**Orthofix Medical Inc. Reports Fiscal Year 2025 Results**
Orthofix Medical Inc. (NASDAQ: OFIX) reported net sales of $822.3 million for the year ended December 31, 2025. This figure includes sales from the company's M6 artificial cervical and lumbar discs. Pro forma net sales, excluding the M6 discs, were $811.9 million, representing a 2.9% increase on a reported basis and a 4.1% increase on a pro forma constant currency basis compared to the previous fiscal year. The company operates through two reporting segments: Global Spine and Global Limb Reconstruction, with Global Spine accounting for 84% of total net sales and Global Limb Reconstruction accounting for 16%.
Within the Global Spine segment, Spine Fixation net sales grew by 10.1% on both a reported and pro forma constant currency basis, including 5.5% growth in U.S. Spine Fixation net sales. Bone Growth Therapies (BGT) net sales reached $247.2 million, a 5.9% increase compared to 2024. The Global Limb Reconstruction segment reported net sales of $134.7 million, an 8.4% increase on a reported basis and a 5.3% increase on a constant currency basis, with U.S. Limb Reconstruction growing by 15.8%. The company's net loss for the year was $92.2 million, compared to a net loss of $126.0 million in the prior year.
Key operational developments included the discontinuation of the M6 artificial disc product lines to focus on more profitable growth opportunities. Research and development expenses decreased to $65.8 million from $73.6 million in the prior year, reflecting resource allocation decisions. The company also highlighted the ongoing integration of legacy businesses following the merger with SeaSpine, with continued efforts to streamline operations and achieve synergies. As of December 31, 2025, Orthofix had 1,605 employees worldwide, with 1,222 in the U.S. and 383 in other non-U.S. locations.
Looking ahead, Orthofix maintains a $275.0 million credit facility secured by substantially all of its property. As of December 31, 2025, the company had $85.1 million in cash, cash equivalents, and restricted cash. The company believes that it will be in compliance with the covenants in future fiscal quarters. The company intends to focus on organic and inorganic innovation, physician collaboration, and partnerships with dedicated and high-performing commercial sales channels to drive future growth.
About Orthofix Medical Inc.
Orthofix Medical Inc. is a global medical technology company specializing in musculoskeletal healing. It offers spinal hardware, biologics, orthopedic solutions, and navigation systems for spine and limb reconstruction. Serving hospitals, clinics, and surgeons worldwide, its core value lies in innovative, minimally invasive devices and regenerative therapies that improve patient outcomes and surgical efficiency through advanced product development and integrated digital platforms.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.